Neuroprotective compound for treating protein misfolding in neurodegenerative diseases
Neurodegenerative diseases, such as Parkinson’s, Alzheimer’s, and Huntington’s, are characterized by misfolded proteins that aggregate and induce neuronal toxicity and death. Protein disulfide isomerase (PDI) is an enzyme implicated in protein misfolding and has been shown to be upregulated in the brains of patients with neurodegenerative diseases. However, the lack of reversibly-binding, selective inhibitors has limited pharmaceutical options for treating conditions associated with elevated PDI activity. This technology is a small molecule compound that reversibly binds to and inhibits PDI activity. As inhibition of PDI has been shown to have neuroprotective effects, this compound is a promising drug candidate for treatment of neurodegenerative diseases.
Inhibition of PDI has neuroprotective effectReversibly binds to PDIHigher affinity to PDI compared to available PDI modulatorsMinimizes toxicity due to non-specific PDI inhibitionPatent Information:Patent Pending (WO/2016/118639)Tech Ventures Reference: IR CU15151
Therapeutic for neurodegenerative conditions related to protein misfoldingTherapeutic for other disorders (e.g. cancer) related to PDI upregulationCreation of PDI-deficient animal models for research
None
美国
